Previous 10 | Next 10 |
Pulmonx Corporation (LUNG) Q4 2020 Earnings Conference Call March 2, 2021 16:30 ET Company Participants Brian Johnston - Investor Relations Glendon French - President & Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Robert Hopkins - Bank of Ame...
Pulmonx (LUNG): Q4 GAAP EPS of -$0.27 beats by $0.01.Revenue of $9.8M (-4.9% Y/Y) beats by $0.99M.Press Release For further details see: Pulmonx EPS beats by $0.01, beats on revenue
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2020 ended Dece...
REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2020 after ...
JTV®, Pulmonx® Corporation & Respiratory Health Association® Launch 2021 Catch Your Breath® Campaign JTV®, Pulmonx® Corporation & Respiratory Health Association® Launch 2021 Catch Your Breath® Campaign National Jewelry Retailer...
Pulmonx has seen a successful public offering back in October. The company is delivering according to expectations, but faces some real COVID-19 headwinds slowing its long-term potential. I like the same long-term potential yet find shares reasonably valued for now, as the near te...
REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG), a pioneer in providing minimally invasive treatment for patients with severe lung disease, welcomes Georgia Garinois-Melenikiotou and Thomas W. Burns to its Board of Directors. Both Directors joined ...
The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1 REDWOOD CITY, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- As part of COPD Awareness Month, Pulmonx Corporation is announcing that over 20,000 patients have been treated worldwid...
Pulmonx (LUNG): Q3 GAAP EPS of -$1.37 beats by $1.39.Revenue of $10.61M (+16.6% Y/Y) beats by $2.66M.2020 Outlook: Expects 2020 revenue to be in the range of $31.5-$32M.Press Release For further details see: Pulmonx EPS beats by $1.39, beats on revenue
REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD, today reported financial results...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...